FDA approves Omvoh for moderately to severely active Crohn's disease

Published Date: 22 Jan 2025

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.

Read Full News

Latest News

Pancreatic Cysts: What’s the Actual Cancer Risk?

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

UTI Treatment Shift: Is Nitrofurantoin Coming Out on Top?

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

Takeda Engaged in Antitrust Scheme to Delay Generic Constipation Drug, US Jury Finds

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Blood Proteins Link Poor Sleep to Increased Cancer Risk

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Housing Instability Tied to Lower Rates of CRC Screening

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

Olanzapine Cuts Radiation-Induced Nausea

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

News All Time

Clinical Pearls to Advance Multidisciplinary Team-Based Care for Patients With GEP-NETs

Clinical Pearls to Advance Multidisciplinary Team-Based Care for Patients With GEP-NETs

Navigating the Future of Upper GI Cancer Treatment: Mechanisms, Personalization, and Expert Insights

Navigating the Future of Upper GI Cancer Treatment: Mechanisms, Personalization, and Expert Insights

Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care

Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care

EASL: European Association for the Study of the Liver

ACG: American College of Gastroenterology

AASLD: American Association for the Study of Liver Diseases

AASLD Video Pearls: Video Pearls from the American Association for the Study of Liver Diseases

CCC: Crohn's & Colitis Congress

Multiple Drugs Flagged for Higher C. Diff Risk

Increased risks observed for analgesics and corticosteroids, among others, in Swedish study

Dulaglutide or Tirzepatide? Worldwide Biopharma Changes

Also in TTHealthWatch: how treatments for hepatitis C have been used

Raw Dairy Farm Recalls Cheese Products as FDA Investigates E. Coli Outbreak

The company initially refused to recall the products

Is Surveillance Colonoscopy Needed for Elderly Patients With Adenomas?

Study finds deaths from other causes far surpass colorectal cancer diagnosis, death

Gaslighting in Gastro Care; Antidepressants and IBS Mortality; Diverticulitis Season

News and commentary from the world of gastroenterology and hepatology

Is Kissing for Celiacs Gluten-Free? Study Weighs In

Small trial finds little in the way of gluten transfer when celiac and non-celiac partners kiss

Strategy Reduces Inappropriate Proton Pump Inhibitor Use

Patient- and physician-facing interventions together doubled the reductions in PPI use

1.8 Billion MASLD Cases; Improving HCC Surveillance; Ultrasound for Crohn's Disease

News and commentary from the world of gastroenterology and hepatology

Recommended News For You

Should the UK introduce targeted prostate cancer screening? The case for and against

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

Fear of hair loss might cause some to reject cancer treatment

Telemedicine services linked to reducing excess mortality

How the skin cancer virus outperforms the replication of host cells.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Recommended Articles For You

Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts 

Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care 

Radiation in Oncology: Advances, Applications, and Accessibility 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.

1.

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training

2.

Hemoglobin C: Understanding its Role in Sickle Cell Disease

3.

Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging

4.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

5.

The Growing Challenge of Haematological Malignancies in Older Adults

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot